[1]王欣欣,袁国盛,赖静兰,等.HBeAg阳性慢性乙型肝炎患者干扰素治疗24周应答不佳时的治疗方案[J].南方医科大学学报,2015,(06):807.
点击复制

HBeAg阳性慢性乙型肝炎患者干扰素治疗24周应答不佳时的治疗方案()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2015年06期
页码:
807
栏目:
出版日期:
2015-06-15

文章信息/Info

Title:
Treatment options in HBeAg-positive chronic hepatitis B patients with a poor response to 24-week interferon monotherapy
作者:
王欣欣袁国盛赖静兰杨年欢张 浩王俊洁周元平
关键词:
乙型肝炎慢性干扰素核苷(酸)类治疗联合
Keywords:
hepatitis B chronic interferon nucleos(t) ides therapy combination
摘要:
目的对干扰素单药治疗24周应答不佳的HBeAg阳性慢性乙型肝炎(CHB)患者采用不同的治疗方案进行后续治疗,分析
比较其疗效和安全性。方法回顾性分析2010年9月~2013年1月南方医科大学南方医院193例干扰素治疗24周时应答不佳的
HBeAg阳性的CHB患者,根据不同后续治疗方案分成:联用恩替卡韦(ETV)或阿德福韦(ADV)治疗(A组),继续干扰素单药治
疗(B组),换为NAs治疗(C组),直接停止治疗(D组)。观察比较第24、48、72周时各组患者的临床疗效与安全性。结果继续治
疗至疗程48 周时,A组和C组HBV DNA转阴率、ALT 复常率均高于B组(A组:χ2=26.808,P<0.001 和χ2=5.485,P=0.017;C
组:χ2=21.257,P<0.001 和χ2=5.369,P=0.018);同时发现,加ETV组HBV DNA转阴率高于加ADV组(χ2=8.255,P=0.004)。疗
程72周时,A组患者有27例(39.7%)发生HBeAg血清学转换,明显高于B、C两组(χ2=4.238,P=0.04 和χ2=7.681,P=0.006);58例
(85.3%)获得HBV DNA转阴,59例(86.8%)ALT恢复正常,均高于B组(χ2=23.018,P<0.001和χ2=5.987,P=0.014),但与C组比
较差异无统计学意义(P>0.05);同时发现,联合ETV组HBV DNA转阴率和HBeAg血清学转换率均高于加ADV组(χ2=9.823,
P=0.002 和χ2=5.450,P=0.020)。D组,28例患者的HBV DNA均持续较高水平复制,HBeAg水平升高,ALT反复波动。结论对
于干扰素单药治疗24周时应答不佳的CHB患者,联用NAs并延长疗程可明显提高HBeAg血清学转换率、HBV DNA转阴率及
ALT复常率,特别是联用ETV并延长疗程时。
Abstract:
Objective To evaluate the efficacy and safety of 4 treatment options for HBeAg-positive chronic hepatitis B (CHB)
patients following a suboptimal response to 24-week interferon monotherapy. Methods The data of 193 HBeAg-positive CHB
patients with suboptimal response to 24-week interferon monotherapy were collected from Nanfang Hospital between
September, 2010 and January, 2013. According to the subsequent treatments, the patients were divided into group A with
additional entecavir or adefovir, group B with further interferon monotherapy, group C with conversion to NAs therapy, and
group D with direct therapy withdrawal, and the biochemical and virological results at weeks 24, 48 and 72 were analyzed in
the 4 groups. Results At week 48, the HBV DNA negative rates and serum alanine aminotransferase (ALT) normalization rates
were both significantly higher in group A and C than in group B (P<0.05); in group A, ETV therapy subgroup had a
significantly higher HBV DNA negative rate than ADV therapy subgroup at week 48 (90.3% vs 59.5%, χ2=8.255, P=0.004). At
week 72, 39.7%(27/68) of the patients in group A achieved HBeAg seroconversion, a rate significantly higher than those in
groups B (χ2=4.238, P=0.040) and C (χ2=7.681, P=0.006); the HBV DNA negative rate and ALT normalization rate in group A
were 85.3%(58/68) and 86.8%(59/68), respectively, both significantly higher than those in group B (χ2=23.018, P<0.001; χ2=5.987,
P=0.014) but comparable to those in group C (P>0.05). In the two subgroups in group A, the HBV DNA negative rate and
HBeAg seroconversion rate were both significantly higher in ETV subgroup (χ2=9.823, P=0.002; χ2=5.450, P=0.020). In group D,
all the patients remained HBeAg-positive with abnormal ALT levels and high level of HBV DNA. Conclusion For HBeAg-positive CHB patients with
suboptimal response to 24-week interferon monotherapy, combined treatment with NAs (especially ETV) and extension of the treatment
course can significantly improve the HBeAg seroconversion rates, HBV DNA negative rates, and ALT normalization rates.

相似文献/References:

[1]刘刚,卢光琇. 湖南汉族人群CTLA4 基因+49G/A 多态性与乙肝感染和乙肝源性肝癌相关性的初步研究[J].南方医科大学学报,2010,(08):1838.
 LIU Gang,LU Guang-xiu.Association of CTLA4 gene +49G/A polymorphism with HBV infection and HBV-relatedhepatocellular carcinoma in Hunan Han population[J].Journal of Southern Medical University,2010,(06):1838.
[2]邹外一,许多荣,苏畅,等. 动态观察慢性髓性白血病患者β-catenin 变化与细胞遗传学疗效的关系[J].南方医科大学学报,2010,(08):1868.
 ZOU Wai-yi,XU Duo-rong,SU Chang,et al. Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship withcytogenetic response[J].Journal of Southern Medical University,2010,(06):1868.
[3]赵金红,王健,江水清,等.慢性乙型肝炎患者CXC趋化因子Mig的表达[J].南方医科大学学报,2006,(11):1589.
 ZHNA Jin-hong,WANG Jian,JIANG Shui-qing,et al.Expression of chemokine monokine induced by interferon-γ in patients with chronic hepatitis B[J].Journal of Southern Medical University,2006,(06):1589.
[4]劳建新,古妙宁,肖金舫,等.羟乙基淀粉血液稀释对慢性肝病患者血液流变学的影响[J].南方医科大学学报,2005,(04):438.
 LAO Jian-xin,GU Miao-ning,XIAO Jin-fang,et al.Effects of hydroxyethyl-starch on hemorheology in patients with chronic liver disease[J].Journal of Southern Medical University,2005,(06):438.
[5]刘俊,刘志强,陶惠琴.血液净化对慢性肾功能衰竭患者全段甲状旁腺激素的影响[J].南方医科大学学报,2004,(02):234.
 LIU Jun,LIU Zhi-qiang,TAO Hui-qin.Effect of blood purification on plasma levels of intact parathyroid hormone in patients with chronic renal failure[J].Journal of Southern Medical University,2004,(06):234.
[6]施斌斌,彭劼,温帆渊,等.百赛诺对慢性乙型肝炎患者细胞免疫应答的影响[J].南方医科大学学报,2005,(06):706.
 SHI Bin-bin,PENG Jie,WEN Fan-yuan,et al.Effect of bicyclol tablets on cellular immune responses in patients with chronic hepatitis B[J].Journal of Southern Medical University,2005,(06):706.
[7]邵咏红,赖玉琼,林爱珍,等.脑钠肽对血液透析患者心功能不全的诊断价值[J].南方医科大学学报,2005,(07):892.
 SHAO Yong-hong,LAI Yu-qiong,LIN Ai-zhen,et al.Value of plasma brain natriuretic peptide detection in cardiac function assessment in hemo-dialysis patients[J].Journal of Southern Medical University,2005,(06):892.
[8]于宏,曹治宸,耿建英,等.干扰素α治疗慢性乙型肝炎患者肝纤维化的实验研究[J].南方医科大学学报,2005,(11):1409.
 YU Hong,CAO Zhi-chen,GENG Jian-ying,et al.Effect of interferon alpha on liver fibrosis in patients with chronic hepatitis B[J].Journal of Southern Medical University,2005,(06):1409.
[9]魏永强,张贤,陈伟伟,等.尼洛替尼治疗伊马替尼耐药或不耐受的慢性粒细胞白血病的长期随访研究[J].南方医科大学学报,2012,(07):1000.
[10]刘表虎,王全师,朱向明,等.实时三维超声节段收缩非同步指数评价慢性心功能不全患者左室非同步运动与收缩功能的关系[J].南方医科大学学报,2012,(08):1122.

更新日期/Last Update: 1900-01-01